CANCER'S CAUSE, CANCER'S CURE (32 page)

Beljanski, M., Crochet, S. The selective anticancer agents PB-100 and BG-8 are active against human melanoma cells, but do not affect non-malignant fibroblasts.
International Journal of Oncology
. 1996. 8: 1143-1148.

35
The original study is from Beljanski, M. “The anticancer agent PB-100, selectively active on malignant cells, inhibits multiplication of sixteen malignant cell lines, even multidrug resistant.”
Genetics and Molecular Biology
, 23, 1, 29-33 (2000). In
Extraordinary Healing
, Stephen Coles has extracted the percentages from the material presented in Beljanski study, 73.

36
Beljanski, M. & Le Goff, L. “Tumor promoter (TPA), DNA chain opening and unscheduled DNA synthesis”.
IRCS Med. Sci.
, 11: 363-364, 1983.

Le Goff, L. & Beljanski, M. “The
in vivo
effects of opines and other compounds on DNAs originating from bacteria and from healthy and tumorous plant tissues.”
Expl. Cell. Biol
. 53: 335-350, 1985.

Beljanski, M.; Le Goff, L.; Beljanski, M.S. “Differential susceptibility of cancer and normal DNA templates allows the detection of carcinogens and anticancer drugs.”
Third NCI-EORTC Symp. On New Drugs in Cancer Therapy
. Institut Bordet, Bruxelles, 1981.

Le Goff, L. & Beljanski, M. “Crown-gall tumor stimulation or inhibition: correlation with DNA strand separation”.
Proc. Fifth Int. Conf. on Plant Path. & Bact.
Cali. pp. 295-307, 1981.

Beljanski, M.; Le Goff, L.; Faivre-Amiot, A. “Preventive and curative anticancer drug. Application to crown-gall tumors.”
Acta Horticulturae
, 125: 239-248, 1982.

Le Goff, L. & Beljanski, M. “Cancer/anti-cancer dual action drugs in crown-gall tumors.”
IRCS Medical Science
, 7: 475, 1979.

In the Oncotest, we have seen that hormones destabilize DNA and therefore act as potential carcinogens. We find again that in plant cancers, hormonal action is necessary (as confirmed by numerous researchers) prior to the induction of cancer in plants. The Beljanski team had researched and developed these studies on cancer induction and inhibition in plants at length and showed, in particular, the essential role of plant hormones in this process. (See Beljanski’s publications # 72, 81, 85, 90, 91, 93, 94, 97, 101, 102, 113 in Appendix C.)

38
Beljanski, M.; Aaron-da-Cunha, Y.; Beljanski, M.S.; Manigual, P.; Bourgarel, P. “Isolation of the tumor-inducing RNA from oncogenic and non-oncogenic
Agrobacterium tumefaciens
.”
Proc. Nat. Acad. Sci
. (USA), 71: 1585-1589, 1974.

Le Goff, L.; Aaron-Da-Cunha, Y.; Beljanski, M. “RNA fraction from several non-oncogenic strains of
Agrobacterium tumefaciens
as tumor-inducing agent in Datura Stramonium”. XIIth Intern. Bot. Congress. Resumes, Leningrad, 1975.

39
J.L. Hall. Springer, D.L. Bemis. “A Novel combination of plant extracts with promising anti-prostate cancer activity.”
Townsend Letter for Doctors and Patients,
Dec, 2004. Information taken from Beljanski study: Beljanski, M., Beljanski, M.S. Three alkaloids as selective destroyers of cancer cells in mice. Synergy with classic anticancer drugs.
Oncology,
1986. 43: 198-203.

40
Extraordinary Healing
, 93-102.

41
Debra Bemis, et al. “A Novel Plant Extract Containing Alkaloids in the B-Carboline Family with Promising Anti-Prostate Cancer Activity.” Columbia University Medical Center College of Physicians and Surgeons. Abstract. Presented to the Society of Integrative Oncology, Nov. 17-19, 2004.

42
Debra Bemis, et al. “β-Carboline Alkaloid-Enriched Extract from the Amazonian Rain forest Tree Pao Pereira Suppresses Prostate Cancer Cells.”
Journal for the Society for Integrative Oncology
, Vol 7, no 2 (spring) 2009. 59-65.

43
Burchill, Melissa. “Two Herbal Extracts for Protecting Prostate Cell DNA.”
Integrative Medicine.
Vol. 9, no. 2, Apr/May 2010. 32-36.

44
Debra Bemis et al. “B-Carboline Alkaloid –Enriched Extract from the Amazonian Rain Forest Re Pao Pereira Suppresses Prostate Cancer Cells.”
Journal for the Society for Integrative Oncology
, Vol 7, no 2 (spring) 2009. 59-65.

45
C.G. Nordau and M.S. Beljanski.
A Pioneer in Biomedicine: Concepts, Theories and Applications
. New York: Edition EVI Liberty Corp, 2000.

46
Mercola, Joseph. www.Mercola.com.

47
Epstein, Samual S.
The Politics of Cancer Revisited
. East Ridge Press, 1998.

48
Beljanski, M. “A new approach to cancer therapy.”
Proceedings of the International Seminar: Traditional Medicine: a Challenge of the 21st Century, Calcutta
(Ed.) Biswapati Mukharjee, 7-9 Nov. 1992.

49
The Merck Manual of Medical Information; Home Edition
. Berkow, R.; Beers, M.H.; Fletcher, A.J., Eds. (Whitehouse Station, New Jersey: Merck Research Laboratories, 1997), pp. 549-551.

50
Schachter, M.B.
The Natural Way to a Healthy Prostate
. (New Canaan, Connecticut: Keats Publishing, Inc., 1995), p. 6.

51
Walker, M. “The urologist with zero tolerance for prostate problems.”
Townsend Letter for Doctors & Patients
201:78-82, April 2001.

Notes To Chapter 5

52
http://ict.sagepub.com

53
http://www.holisticurology.columbia.edu/_aboutus/Mission.html. July 21, 2011.

54
Jonathan Weiner. “The Mind of a Disease.”
New York Times Book Review.
Nov 12, 2010. (http://www.nytimes.com/2010/11/14/books/ review/Weiner-t.html.)

55
Burchill, Melissa. “Two Herbal Extracts for Protecting Prostate Cell DNA.”
Integrative Medicine
. Vol. 9, no. 2, Apr/May 2010. 36.

56
M. Beljanski, M.S. Beljanski. ‘Three alkaloids as selective destroyers of cancer cells in mice. Synergy with classic anticancer drugs.”
Onkologie
, 43, 1986, pp. 198-203.

Nordau C. G. and Monique Beljanski.
A Pioneer in Medicine: Concepts, Theories, Applications.
New York: EVI Liberty Corp, 2000.

57
Extraordinary Healing,
pg. 41.

58
A Pioneer in Biomedicine, chapter 3.

59
Coles, L. Stephen. “RNA Fragments, Anti-Aging, and Immune Health”
The Doctors’ Prescription for Healthy Living
. Sept. 2009.

60
MedicineNet.com. http://www.medterms.com/script/main/art. asp?articlekey=5367 May 5, 2011.

61
BELJANSKI, M.; BELJANSKI, M. S.; PLAWECKI, M.; MANIGAULT, P. “ARN-fragments, amorceurs nécessaires ˆ la réplication in vitro È des ADN.”
C.R. Acad. Sci.
, 280:363-366, 1975, (série D).

62
BELJANSKI, M.; PLAWECKI, M.; BOURGAREL, P.; BELJANSKI, M.S. “Leucocyte recovery with short-chain RNA fragments in cyclophosphamide-treated rabbits.”
Cancer Treatment Reports
. 67: 611-619, 1983.

63
BELJANSKI, M.; PLAWECKI, M.; BOURGAREL, P.; BELJANSKI, M.S. “Nouvelles substances (R.L.B.) actives dans la leucopo•ﾏse et la formation des plaquettes.” Bull. Acad. Nat. Med., 162(6) :475-781, 1978.

BELJANSKI, M. & PLAWECKI, M. “Particular RNA fragments as promoters of leukocyte and platelet formations in rabbits”.
Exp. Cell Biol.
, 1979, 47, pp. 218-225.

BELJANSKI, M. “Oligoribo-nucleotides, promoters of leucocyte and platelet genesis in animals depleted by anticancer drugs”. NCI-EORTC
Symposium on nature, prevention and treatment of clinical toxicity of anticancer agents.
Institut Bordet, Bruxelles, 1980.

BELJANSKI, M.; PLAWECKI, M.; BOURGAREL, P.; BELJANSKI, M.S. “Short chain RNA fragments as promoters of leucocyte and platelet genesis in animals depleted by anti-cancer drugs”. In
The Role of RNA in Development and Reproduction
. Sec. Int. Symposium, M.C. Niu and H.H. Chuang Eds Van Nostrand Reinhold Company. (Beijing: Science Press, April 25-30, 1980), pp.79-113.

PLAWECKI, M. & BELJANSKI, M. “Comparative study of
Escherichia coli
endotoxin. Hydrocortisone and Beljanski leucocyte restorer activity in cyclophosphamide-treated rabbits.”
Proc. of the Soc. for Exp. Biol. and Med.
, 168: 408-413, 1981.

DONADIO, D.; LORHO, R.; CAUSSE, J.E.; NAWROCKI, T.; BELJANSKI, M. “RNA fragments (RLB) and tolerance of cytostatic treatments in hematology: A preliminary study about two non-Hodgkin malignant lymphoma cases.”
Deutsche Zeitschrift für Onkologie
, 23(2): 33-35, 1991. (OLD NOTE 39-43)

64
Schachter, Michael, M.D., CNS. “Integrative Oncology for Clinicians and Cancer Patients.” From an expanded lecture presented at the International Society of Integrative Medicine meeting in Tokyo, Japan on July 19, 2009. From http://www.breastcancerchoices.org/ files/Schachter_PDF_File_from_ICIM_Journal.pdf.

65
Robert D. Levin, MaryAnn Daehler, James F. Grutsch, John L. Hall, Dignant Gupta, Christopher G. Lis. “Dose escalation study of antithrombocytopenic agent in patients with chemotherapy induced thrombocytopenia.” BMC Cancer 2010, 10:565. http://www.biomedcentral.com/1471-2407/10/565.

66
L. Stephen Coles, M.D., Ph.D. “RNA Fragments, Anti-aging Medicine and Immune Health.”
The Doctors’ Prescription for Healthy Living
. September, 2009. pg. 25-26.

67
John W. Gofman, MD, Ph.D. “Radiation from Medical Procedures in the Pathogenesis of Cancer and Ischemic Heart Disease: Dose-Response Studies with Physicians per 100,000 Population” San Francisco: Committee for Nuclear Responsibility, Inc., 1999.

68
Kaplan. Adv. Dermatol. 2: 19-46, 1987.

69
Extraordinary Healing
, 53-55.

70
Soloman, P.R.; Adams, F., et al. “
Ginkgo
for memory enhancement: a randomized controlled trial.”
JAMA
288 (7):835-840, 2002.

Burns, N.R.; Bryan, J.; Nettelbeck, T. “
Ginkgo biloba
: no robust effect on cognitive abilities or mood in healthy, young or older adults.”
Hum. Psycho. Pharmacol.
Dec. 2005. Clostre, F. “
Ginkgo biloba
extract. State of knowledge in the dawn of the year 2000.”
Ann. Pharm.
Fr. 57 Suppl. 1:158-188, 1990.

71
Rosen, I.; Fischer, T., et al. “Correlation between lung fibrosis and radiation therapy dose after concurrent radiation therapy and chemotherapy for limited small cell lung cancer.”
Radiology
; 221:614, 2001.

72
Saflotti, V.; Shubik, R. “The role of burning in carcinogenesis.”
Br. J. Cancer,
10:54-57, 1956. Sirsat, M.V. & Shrikhande, S.S. “Histochemical studies on squamous cell carcinomas of the skin arising in burn scars with special reference to histogenesis.”
Indian J. Cancer
3:157-169, 1967.

Beljanski, M. “Radioprotection of irradiated; mice-mechanisms and synergistic action of WR-2721 and R.L.B.”
Deutsche Zeitschrift ur Onkologie
, 23(6): 155-159, 1991.

73
Natural Source International, the company who manufactures the Beljanski products, in conjunction with CIRIS, conducted the survey, tabulated the results, and shared the information in their newsletter.

74
Beljanski, M. “Radioprotection of irradiated; mice-mechanisms and synergistic action of WR-2721 and R.L.B.”
Deutsche Zeitschrift ur Onkologie
, 23(6): 155-159, 1991.

Causse, J.E.; Nawrocki, T.; Beljanski, M. “Human skin fibrosis RNase search for a biological inhibitor-regulator”: -
Deut. Zeit. Fur Onk.
, 26, 5, 1994, pp. 137-139.

Nordau, C.G. & Beljanski, M.
A Pioneer in Biomedicine,
(New York: EVI Liberty Corp., 2003), pp. 66, 116, 122.
75
Le Goff, L. & Beljanski, M. “Cancer/anticancer dual action drugs in crown- gall tumors.”
IRCS Medical Science,
7:475, 1979.

Beljanski, M.; Le Goff, L.; Beljanski, M.S. “In vitro screening of carcinogens using DNA of the His-Mutant of
Salmonella typhimurium
.” Experimental Cellular Biology, 50: 271-280, 1982.

Beljanski, M. & Le Goff, L. “Tumor promoter (TPA), DNA chain opening and unscheduled DNA synthesis.”
IRCS Medical Science,
11: 363-364, 1983.

76
Hoffmann, D.
The Complete Illustrated Holistic Herbal: a Safe and Practical Guide to Making and Using Herbal Remedies
. (New York: Barnes and Noble Books, 1996), P. 101.

Notes To Chapter 6

77
Le Perlier, J.P.
Enguete Sur un Survivant Illegal.
(Paris: Ed. Guy Tredaniel Publishing Co., 2002).